CVR: 39859173
Previous names: Ebumab ApS
Cymab ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2018. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Ebumab ApS. The management consists of Johan Henrik Faber. The company is owned by Johan Henrik Faber and Ebumab Holding ApS. In 2025, the company reported a gross profit of DKK -5,463,240 and a net result of DKK -7,576,022 compared with DKK -4,627,624 the year before. Equity amounted to DKK -20,227,476.
Your company? Claim the profile and show your logo, website and social channels — for free.
Claim this profileSelskabets formål er at drive virksomhed indenfor forskning, udvikling og markedsføring af farmaceutiske og medicinske præparater samt anden efter bestyrelsens skøn beslægtet virksomhed.
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringCompared to 129 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Cymab ApS has published its annual report for 2025. Gross profit came to DKK -5,463,240, and the net result was DKK -7,576,022.
As of February 6, 2026, Anne Reker Cordt has left the board of directors of Cymab ApS.
As of February 6, 2026, Anne Reker Cordt has stepped down as director of Cymab ApS.
Cymab ApS has published its annual report for 2024. Gross profit came to DKK -1,951,697, and the net result was DKK -4,627,624.
As of February 25, 2025, Beierholm Godkendt Revisionspartnerselskab has been appointed auditor of Cymab ApS.
As of February 25, 2025, Slotsgade Revision ApS has stepped down as auditor of Cymab ApS.
Cymab ApS has published its annual report for 2023. Gross profit came to DKK -1,206,027, and the net result was DKK -2,580,789.
As of June 24, 2024, Anne Reker Cordt has joined the board of directors of Cymab ApS.
As of June 24, 2024, Anne Reker Cordt is registered as director of Cymab ApS.
As of May 31, 2024, Stine Louise Reedtz Kjellev has stepped down as director of Cymab ApS.
Cymab ApS has published its annual report for 2022. Revenue came to DKK 0, and the net result was DKK -1,541,246.
As of April 17, 2023, Hans Heugh Wandall has joined the board of directors of Cymab ApS.
As of April 17, 2023, Thomas Dal Stenfeldt Batchelor has joined the board of directors of Cymab ApS.
As of April 17, 2023, Mads Nikolaj Behrndt-Eriksen has joined the board of directors of Cymab ApS.
As of April 17, 2023, Johan Henrik Faber is registered as adm. dir. of Cymab ApS.
As of April 17, 2023, Stine Louise Reedtz Kjellev is registered as director of Cymab ApS.
As of April 17, 2023, Hans Heugh Wandall has stepped down as adm. dir. of Cymab ApS.
On April 17, 2023, the company changed its name from Ebumab ApS to Cymab ApS.
As of April 16, 2023, Hans Heugh Wandall has left the board of directors of Cymab ApS.
As of April 16, 2023, Thomas Dal Stenfeldt Batchelor has left the board of directors of Cymab ApS.
As of April 16, 2023, Johan Henrik Faber has stepped down as director of Cymab ApS.
Cymab ApS has published its annual report for 2021. Gross profit came to DKK -566,735, and the net result was DKK -942,533.
Cymab ApS has published its annual report for 2020. Revenue came to DKK 0, and the net result was DKK -955,753.
As of May 21, 2021, Hans Heugh Wandall has joined the board of directors of Cymab ApS.
As of May 21, 2021, Thomas Dal Stenfeldt Batchelor has joined the board of directors of Cymab ApS.
As of May 21, 2021, Hans Heugh Wandall is registered as adm. dir. of Cymab ApS.
As of May 20, 2021, Hans Heugh Wandall has left the board of directors of Cymab ApS.
As of May 20, 2021, Thomas Dal Stenfeldt Batchelor has left the board of directors of Cymab ApS.
As of November 25, 2020, Johan Henrik Faber is registered as an owner of Cymab ApS with an ownership share of 31%.
Cymab ApS has published its interim report for the period September 10, 2018 – December 31, 2019.
As of July 15, 2020, Slotsgade Revision ApS has been appointed auditor of Cymab ApS.
As of July 15, 2020, KAPPELSKOV REVISION. GODKENDT REVISIONSAKTIESELSKAB has stepped down as auditor of Cymab ApS.
As of June 22, 2020, Hans Heugh Wandall has joined the board of directors of Cymab ApS.
As of June 22, 2020, Søren Erik Bjørn has joined the board of directors of Cymab ApS.
As of June 22, 2020, Kim Stengaard Holmsted has left the board of directors of Cymab ApS.
As of June 21, 2020, Hans Heugh Wandall has left the board of directors of Cymab ApS.
As of June 1, 2019, Johan Henrik Faber has joined the board of directors of Cymab ApS.
As of June 1, 2019, Thomas Dal Stenfeldt Batchelor has joined the board of directors of Cymab ApS.
As of June 1, 2019, Kurt Flemming Holmsted has left the board of directors of Cymab ApS.
As of June 1, 2019, Johan Henrik Faber is registered as director of Cymab ApS.
As of June 1, 2019, Kurt Flemming Holmsted has stepped down as director of Cymab ApS.
As of September 10, 2018, KAPPELSKOV REVISION. GODKENDT REVISIONSAKTIESELSKAB has been appointed auditor of Cymab ApS.
As of September 10, 2018, Kurt Flemming Holmsted has joined the board of directors of Cymab ApS.
As of September 10, 2018, Hans Heugh Wandall has joined the board of directors of Cymab ApS.
As of September 10, 2018, Kim Stengaard Holmsted has joined the board of directors of Cymab ApS.
As of September 10, 2018, Kurt Flemming Holmsted is registered as director of Cymab ApS.
As of September 10, 2018, Ebumab Holding ApS is registered as an owner of Cymab ApS with an ownership share of 100%.
Cymab ApS was founded on September 10, 2018.
Companies in the same industry and area
CVR 38402056
CVR 39880377
CVR 42057428
CVR 43432583
CVR 43575627
companydata.dk